Kymera Therapeutics, Inc. SEC filings KYMR
Kymera Therapeutics, Inc. has 647 filings in SEC EDGAR's recent list, going back to Jun 22, 2020. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| CORRESP | Letter to the SEC | Apr 30, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 25, 2025 | — |
| EFFECT | Filing | Jun 30, 2021 | — |
| CORRESP | Letter to the SEC | Jun 28, 2021 | — |
| CORRESP | Letter to the SEC | Jun 28, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 19, 2021 | — |
| DRS | Filing | Mar 17, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 11, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 10, 2021 | — |
| EFFECT | Filing | Aug 20, 2020 | — |
| CERT | 8a cert | Aug 20, 2020 | — |
| 8-A12B | Filing | Aug 18, 2020 | — |
| CORRESP | Letter to the SEC | Aug 18, 2020 | — |
| CORRESP | Letter to the SEC | Aug 18, 2020 | — |
| CORRESP | Letter to the SEC | Aug 13, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2020 | — |
| CORRESP | Letter to the SEC | Aug 5, 2020 | — |
| CORRESP | Letter to the SEC | Jul 31, 2020 | — |
| UPLOAD | Letter from the SEC | Jul 17, 2020 | — |
| DRS | Filing | Jun 22, 2020 | — |
Showing 21 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KYMR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1815442
- Former names
- Kymera Therapeutics, Inc. (until Oct 29, 2026)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.